Join Jasper Therapeutics for a virtual KOL event, featuring Joshua A. Boyce, MD, Harvard Medical School who will join company management to discuss the unmet medical need, current treatment landscape, and clinical development plans for new briquilimab indication in asthma.

The event will focus on the scientific rationale and preclinical data supporting development of briquilimab for the treatment of asthma via mast cell depletion, as well as plans for clinical development. Briquilimab is a novel antibody therapy targeting c-Kit (CD117) with the potential to remove a key driver of the inflammatory response in mast cell diseases.

A live question and answer session will follow the formal presentations.